Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Submitted by
admin
on February 13, 2013 - 10:16am
Source:
Motley Fool
News Tags:
JNJ
Multiple Myeloma
Velcade
Celgene
Revlimid
AbbVie
ONYX Pharmaceuticals
Bristol-Myers Squibb
Headline:
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Do Not Allow Advertisers to Use My Personal information
